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L-arginineThe m.3243A>G variant in the mitochondrial tRNALeu(UUR) gene is a common mitochondrial DNA (mtDNA)
mutation. Phenotypic manifestations depend mainly on the heteroplasmy, i.e. the ratio of mutant to normal
mtDNA copies. A high percentage of mutant mtDNA is associated with a severe, life-threatening neurological
syndrome known as MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like epi-
sodes). MELAS is described as a neurovascular disorder primarily affecting the brain and blood vessels, but
the pathophysiology of the disease is poorly understood.
We developed a series of cybrid cell lines at two different mutant loads: 70% and 100% in the nuclear back-
ground of a neuroblastoma cell line (SH-SY5Y). We investigated the impact of the mutation on the metabo-
lism and mitochondrial respiratory chain activity of the cybrids. The m.3243A>G mitochondrial mutation
induced a metabolic switch towards glycolysis in the neuronal cells and produced severe defects in respira-
tory chain assembly and activity. We used two strategies to compensate for the biochemical defects in the
mutant cells: one consisted of lowering the glucose content in the culture medium, and the other involved
the addition of L-arginine. The reduction of glucose signiﬁcantly shifted the 100% mutant cells towards the
wild-type, reaching a 90% mutant level and restoring respiratory chain complex assembly. The addition of
L-arginine, a nitric oxide (NO) donor, improved complex I activity in the mutant cells in which the defective
NO metabolism had led to a relative shortage of NO. Thus, metabolically induced heteroplasmy shifting and
L-arginine therapy may constitute promising therapeutic strategies against MELAS.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial oxidative phosphorylation carried out by respirato-
ry chain complexes embedded in the mitochondrial inner membrane
produces most of the energy required by eukaryotic cells [1]. Elec-
trons produced by the oxidation of the substrate are transferred
from complexes I and II to complex IV. The proton-motive force creat-
ed by proton translocation through complexes I, III and IV is used by
ATP synthase to phosphorylate ADP into ATP. The oxidation andtochrome c oxidase; FBS, fetal
ione; LDH, lactate dehydroge-
A, mitochondrial DNA; MELAS,
, and stroke-like episodes; NO,
rphism; ROS, reactive oxygen
cs Laboratory, National Centre
U Angers, 4 rue Larrey, 49933
35 58 83.
ccio).
rights reserved.phosphorylation processes are thus tightly coupled. However, in
physiological and particularly in pathological conditions, electrons
transported across the different respiratory chain complexes may ac-
cumulate and produce reactive oxygen species (ROS). Free radicals,
generated mainly by complexes I and III, trigger cell-damaging oxida-
tive stress.
The proteins of the respiratory chain complexes are encoded by a
combination of mitochondrial and nuclear genes [2]. MtDNA is a
16,569 bp double-stranded circular DNA molecule encoding 13 poly-
peptides, 2 ribosomal RNAs and 22 transfer RNAs. Mutations in the
mitochondrial or the nuclear genomes may thus lead to respiratory
chain dysfunction, and ultimately to mitochondrial diseases. Since
the initial description of the ﬁrst human mtDNA mutation in 1988,
more than 200 pathogenic mutations have been associated with a
wide variety of human diseases [3]. One of the most frequently ob-
served mtDNA mutations is the A-to-G transition at position 3243 of
the tRNALeu(UUR) gene, which has been shown to impair mitochondri-
al structure, methylation, amino-acylation and codon recognition of
the tRNALeu [4]. This mutation, which gives rise to a wide range of
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erance to exercise, is predominant in about 80% of the patients with
MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis
and stroke-like episodes; OMIM 540000) [5]. The variability of the
phenotypes associated with the mutation may be partially explained
by the level of heteroplasmy [6]. Indeed, mutant and wild type
mtDNA copies coexist in cells in various proportions, resulting in dif-
ferent mutation loads in tissues or organs. The heteroplasmy level
may thus shift during cell division due to random segregation of mu-
tant or wild-type mtDNA. Hence, the ratio of mutant to normal
mtDNA, and the speciﬁc tissue affected, may determine the severity
of the disease [6]. The m.3243A>Gmutation causes diabetes mellitus,
with or without deafness [7]. However, with a higher proportion of
mutants, the samemutation may lead to chronic progressive ophthal-
moplegia, cardiomyopathy, or the complete MELAS syndrome [1].
Generally, a ﬁrst episode of stroke in MELAS patients occurs between
the ages of 5 to 15 years, although it may occur at any time from in-
fancy to adulthood [5,8]. In addition, maternal relatives may suffer
from a variety of complex clinical problems involving the central ner-
vous system, muscle, heart, kidneys and the endocrine system.
Stroke-like episodes, which do not respect vascular territories, are
usually reversible, allowing partial or almost complete recovery [8].
The speciﬁcity ofMELASwith early-onset of stroke-like episodes is at-
tributed to endothelial dysfunction since degenerative changes, associat-
ed with several mitochondrial abnormalities, has been described in the
endothelial and smooth muscle cells of cerebral small arteries [9,10].
Nitric oxide (NO), themainmediator of endothelial relaxation, is primar-
ily generated by NO synthesis from L-arginine. Hence, L-arginine supple-
mentation, which donates NO, alleviates endothelial dysfunction in
MELAS patients suggesting that the NO metabolism plays an important
role in the pathophysiology of MELAS [9,11,12].
Several pathophysiological studies have reported a mitochondrial
dysfunction associated with a severe reduction of the activities of com-
plexes I and IV of the respiratory chain in MELAS patient cells [13,14]. A
reduction of aminoacylation of the tRNALeu(UUR) and the rate of mito-
chondrial protein synthesis has been reported in transmitochondrial
mutant cell lines [15,16]. Mutant loads exceeding 90% have led to the
decline of protein synthesis as well that of oxygen consumption of the
cells [17]. These studies were performed on muscle tissue and ﬁbro-
blasts fromMELAS patients, and cybrid cells originating from143Boste-
osarcoma cells; however, only a few authors have reported the
mitochondrial effects of the m.3243A>G mutation on the organs most
affected in the disease, i.e. the brain and blood vessels [8,18].
Neuroblastoma cell lines such as SH-SY5Y cells have been used as
a neuronal-like model to create transmitochondrial cybrids carrying
deﬁcient mitochondria from Parkinson's or Alzheimer's disease pa-
tients, showing that the mitochondrial defect was transferred to the
cybrid cell lines [19,20].
To analyze the consequences of the m.3243A>G mutation on mi-
tochondrial metabolism in a neuronal like model, we developed a se-
ries of SH-SY5Y transmitochondrial cybrid cells carrying 70% and
100%mutant loads, indicated below as 70%M and 100%M cybrids, re-
spectively. Our study showed that the mutation modiﬁed the ener-
getic metabolism of the cybrids, producing a metabolic switch
towards glycolysis. Furthermore, the mutation severely altered the
assembly and functions of the mitochondrial respiratory chain and in-
duced an increase in oxidative stress.
No efﬁcient treatment is currently available for mitochondrial dis-
orders, including MELAS. A better understanding of the pathophysio-
logical mechanisms triggered by the m.3243A>G mutation should
help to deﬁne an effective therapeutic strategy for the disease [2].
Overexpression of the mitochondrial leucyl-tRNA synthetase in
cybrid cells carrying the MELAS mutation resulted in the restoration
of the respiratory chain function of the mutant cells [21]. Based on
the hypothesis that stroke-like episodes are the consequence of a seg-
mental impairment of vasodilation in small arteries, L-arginine hasbeen proposed as a treatment for MELAS m.3243A>G syndrome pa-
tients during the acute stroke phase or long term use [9,11,12,22].
Thus, we used two experimental approaches to reduce mitochondrial
dysfunction. The ﬁrst approach involved cultivating the cybrid cells in
a medium low in glucose so as to induce a heteroplasmic shift of the
mutants to the wild type. The second approach consisted of treating
the cybrid cells with L-arginine, known to be an NO donor, to investi-
gate the role of L-arginine in the pathophysiology of MELAS.
2. Material and methods
2.1. Cell culture and transmitochondrial cybrids
The SH-SY5Y human parental neuroblastoma cell line was
obtained from the American Type Culture Collection (ATCC), and cul-
tured in DMEM high-glucose medium (PAA) supplemented with 10%
fetal bovine serum (FBS, PAA), 2 mM L-glutamine, and antibiotics
(100 U/ml penicillin G, 2 mM streptomycin and 0.25 μg/ml amphop-
tericin B, Institut de Biotechnologies Jacques Boy). Cells were grown
in 75 cm² ﬂasks at 37 °C in a humidiﬁed atmosphere (95% air and
5% CO2). Mitochondrial respiratory deﬁcient ﬁbroblasts were cultured
in 2/3 DMEM F-12, 1/3 Amniomax (Gibco) medium supplemented
with 10% SVF (PAA), 100 μg/ml sodium pyruvate and 50 μg/ml uri-
dine (Sigma-Aldrich).
The generation of neuronal-like cybrid cell lines was realized as
described elsewhere [23]. Brieﬂy, SH-SY5Y cells were depleted of
mtDNA with a rhodamine-6-G treatment (2.5 μg/ml) during 5 days.
Fibroblasts from patients carrying the m.3243A>G mutation were
enucleated by actinomycin D treatment (0.5 μg/ml for 14 h). The
cells were washed with complete DMEM and mixed SH-SY5Y/enucle-
ated ﬁbroblast cells were then fused with the addition of polyethyle-
neglycol (PEG 1500, Roche Applied Science). After 1 min, the cells
were washed and centrifuged twice (300 g, 5 min) with DMEM high
glucose, 10% FBS to eliminate the PEG, and the pellet was resus-
pended in the SH-SY5Y cell media. The medium was replaced by
high-glucose DMEM, 10% FBS for 3 days to eliminate non-fused
cells, and propagated to select independent clones.
2.2. Glucose, lactate and pyruvate measurements
Glucose and lactate concentrations in the culture media were de-
termined by spectrophotometry, using appropriate enzymatic kits
(Boerhinger) on a Hitachi-Roche apparatus (Roche Diagnostics). Py-
ruvate concentration was determined by measuring the NADH reduc-
tion in the presence of the lactate dehydrogenase enzyme using
spectrophotometry at 340 nm.
2.3. MtDNA analysis and quantiﬁcation of heteroplasmy
Total DNA was extracted from cells with High Pure PCR Template
Preparation Kit (Roche Applied) in accordance with the manufacturer's
instructions. The PCR-ampliﬁed mtDNA fragments of control SH-SY5Y
cells and 100%mutants were determined by full sequencing as described
elsewhere [24]. The quantiﬁcation of mutant loads in SH-SY5Y cybrids
was determined by ﬂuorescent RFLP (restriction fragment length poly-
morphism) and monitored on a regular basis during the experiments as
shown before [25]. A 262 bp DNA fragment surrounding the
m.3243A>G mutation was ampliﬁed by PCR using ﬂuorescent
hmtL3117 (5′-FAM-CCCTGTACGAAAGGACAAGAGAAATAACGCC-3′) and
non ﬂuorescent hmtH3381 (5′-CGTTCGGTAAGCATTAGGAATGCCATTGC-
3′) primers. PCR products were digested with HaeIII restriction enzyme
(New England Biolabs) which cleaves the mutant DNA into 3 fragments
(a 123 bp ﬂuorescent fragment, and 73 bp and 66 bp non-ﬂuorescent
fragments) and thewild-typeDNA into 2 fragments (a 196 bpﬂuorescent
fragment and a 66 bp non-ﬂuorescent fragment). Fragments were sepa-
rated on polyacrylamide gel capillaries of a fragment analyzer (3130xl
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determined by migration comparison with a ﬂuorescent DNA size ladder
(Genescan 600LIZ, Applied Biosystems). Data were analyzed with Peak
Scanner software (Applied Biosystems) and themutant loadwas calculat-
ed using mutant and wild type peak areas.
2.4. Enzymatic activity measurements of the respiratory chain complexes
Activities of complexes I, II and IV of the respiratory chain of SH-SY5Y
parental and mutant cells were measured as described elsewhere [26].
Brieﬂy, cell pellets were resuspended in a volume of 50 μl/million cells
of cell buffer (saccharose 250 mM, TRIS 20 mM, EDTA 2mM, BSA 1mg/
ml, pH 7.4). After a freezing–thawing cycle, cells were centrifuged
(16,000 rpm, 1 min) and resuspended in the same volume of cell buffer.
For complex I activity measurement, an additional step of sonication (6
cycles of 5 s with a 30 s stop) was required. One million cells were then
incubated at 37 °C in a reaction medium (KH2PO4 100 mM, pH 7.4, KCN
1mM, NaN3 2 mM, BSA 1mg/ml, ubiquinone-1 0.1 mM and DCPIP
0.075 mM). The reaction was started by adding 0.3 mM NADH and the
disappearing rate of DCPIP was measured at 600 nm for 2 min. The
unspeciﬁc activity was determined by adding rotenone 0.005 mM at the
middle of the kinetic. For complex II activity, 0.5 million cells were
added to a reaction buffer (KH2PO4 100 mM, pH 7.5, KCN 2mM, EDTA
0.1 mM, BSA 1mg/ml, rotenone 0.01 mM, antimycin 0.002 mg/ml, succi-
nate 20 mM and DCPIP 0.08 mM) and the reaction was initiated by add-
ing 0.005 mM of ubiquinone-1. The disappearing rate of DCPIP was
measured at 600 nm and the background was subtracted by using the-
noyltriﬂuoroacetone 200 μM. For complex IV, a volume equivalent to
0.1 million cells was added to the reactionmedium (reduced cytochrome
c 0.05 mM, BSA 1mg/ml, laurylmaltoside 0.250 mM) and the oxidation
rate of reduced cytochrome cwas monitored at 550 nm.
The enzymatic activities of the respiratory chain complexes were
normalized with respect to citrate synthase activity, which is consid-
ered as a marker of mitochondrial mass. This activity was measured
by adding 0.1 million cells to a prewarmed reaction mix (DTNB
0.15 mM, oxaloacetic acid 0.5 mM, acetyl coA 0.3 mM, Triton X100
0.1%) and the appearing rate of coA-SH was measured at 412 nm.
2.5. Measurement of aconitase activity
Aconitase activity was measured on 1 million frozen SH-SY5Y cells
resuspended in the cell buffer and incubated in the reaction buffer
(Tris 50 mM, pH 7.4, MnCl2 0.5 mM, sodium isocitrate 20 mM, Triton
0.01%. The appearing rate of cis-aconitate was monitored at 240 nm.
Activity was normalized with respect to citrate synthase activity as
described above.
2.6. Oxygen consumption on permeabilized SH-SY5Y cells
Cells were trypsinized and the pellet was resuspended in the respi-
ratory buffer (KH2PO4 10 mM, mannitol 300 mM, KCl 10 mM, MgCl2
5 mM, pH 7.4) containing 15 μg/million cells of digitonin. Cells were in-
cubated at room temperature during 2.5 min and the digitonin action
was stopped by adding ﬁve volumes of the respiration buffer supple-
mented with 1 mg/ml of BSA. Cells were centrifuged (800 rpm,
2.5 min), resuspended in the respiration buffer+BSA (50 μl/million of
cells) and placed in the oxygraph chamber (Oroboros). The oxygen con-
sumption was measured in state II (5 mMmalate+pyruvate), state III
(5 mMmalate+pyruvate+1.5 mM ADP+0.5 mM NAD or 5 mM suc-
cinate+10 μM rotenone+1.5 mM ADP+0.5 mM NAD), state IV
(8 μg/ml oligomycin) and maximal cytochrome c oxidase capacity
(4 mM ascorbate+0.2 mM TMPD). Non-mitochondrial oxygen con-
sumption was subtracted by adding antimycin (2.5 μg/ml). After oxy-
graphic measurement, 400 μl of cell suspension was removed from
the chamber and the protein concentration was measured using
bicinchoninic acid.2.7. ATP measurement
SH-SY5Y control and mutant cells were seeded in 24-well plates
and at 80% of conﬂuence, medium was removed and replaced by
the extraction buffer (boric acid 0.2 M, magnesium sulfate 10 mM,
Triton X100 0.1%, pH 9.2) for 10 min on ice. The supernatant was re-
moved and centrifuged at 1000 g for 5 min and immediately frozen at
−80 °C. ATP was then assayed with the luciferin-luciferase-based kit
(ENLITEN ATP Assay System, Promega).
2.8. Deconvolution microscopy and mitochondrial network analysis
Mitochondria were labeled using Mitotracker® Green 100 nM
(Molecular Probes). Images were acquired with an inverted wide-
ﬁeld Leica microscope (DMI6000B, Microsystems) equipped with a
Roper CoolSnap HQ2 camera (Roper Scientiﬁc) a high-sensitivity
CCD camera for quantitative ﬂuorescence microscopy. Metamorph®
7.7 software (Molecular Devices) was used for image acquisition
and Huygens software (Scientiﬁc Volume Imaging) for deconvolution.
Imaris 7.1.1® software (Bitplane) was used for 3D processing and
morphometric analysis.
2.9. Western blotting
Frozen pellets of SH-SY5Y cells were resuspended in a 10 μl/mil-
lion of 1× protease inhibitor cocktail (Complete Protease Inhibitor
Cocktail Tablets, Roche Applied Science). A volume corresponding to
40 μg protein was added to a sample buffer (Tris 0.1 M, SDS 1.2%,
glycerol 4.1 M, bromophenol blue 2%, 2β mercaptoethanol 1.87 M),
boiled for 5 min and loaded on 12.5%. Proteins were separated by
electrophoresis and transferred onto PVDF membranes (GE Health-
care). Membranes were blocked with TBS 1× (NaCl 0.8%, KCl 0.02%,
Tris 0.3%, pH 7.4), Tween 0.01%, 5% non-fat milk for 2 h and incubated
with primary antibodies (MnSOD, Abcam, 1:2000; Total OXPHOS
HumanWB Antibody Cocktail, Mitosciences, 1:1000) overnight at
4 °C. Incubation with a secondary antibody (anti-mouse or anti-
rabbit, GE Healthcare, 1:10,000) was performed for 2 h at room tem-
perature. Proteins were detected by enhanced chemiluminescence
(ECL plus, GE Healthcare) and quantiﬁed using Quantity One software
(BioRad). Tubulin antibody (Calbiochem, 1:2000) was used as loading
control.
2.10. Blue-Native PAGE of respiratory chain complexes
Frozen pellets of SH-SY5Y cells were resuspended in 1× PBS. Mito-
chondria were extracted by digitonin permeabilization (2 mg/ml)
and centrifugation (10,000 g, 10 min). The mitochondria-enriched
pellet was resuspended in the sample buffer (aminocaproic acid
1.5 M, bis tris pH 7.0 75 mM, protease inhibitor cocktail 1×) and
mixed with laurylmaltoside (2 g/g protein). The suspension was incu-
bated for 10 min on ice and centrifuged at 10,000 g for 30 min. Isolat-
ed mitochondrial proteins were loaded onto a 4–15% bis-acrylamide
gradient gel. The complexes were then transferred onto PVDF mem-
branes. Membranes were saturated for 2 h on TBS1×/Tween 0.01%/
10% non-fat milk and incubated with primary antibody (for complex
I: NDUFB6, 1:1000, for complex IV: COXI, 1:1000, and for complex V:
V beta 1:1000, Mitosciences). Antibody against complex II 70 kDa,
1:1000 was used as loading control. Membranes were washed twice
and incubated with secondary anti-mouse antibody (1:10,000, GE
Healthcare) and the complex assembly was visualized using en-
hanced chemiluminescence (ECL Plus, GE Healthcare).
2.11. Measurement of nitrates+nitrites
The concentration of nitrates+nitrites was measured on the cul-
ture supernatant of SH-SY5Y control and mutant cells using the
1022 V. Desquiret-Dumas et al. / Biochimica et Biophysica Acta 1822 (2012) 1019–1029colorimetric Nitric Oxide Synthase Assay Kit (Calbiochem), following
the manufacturer's instructions. Brieﬂy, the reaction is based on the
conversion of nitrites to an azo product by Griess reagents (sulfanil-
amide and N-(1-naphtyl) ethylenediamine). The azo product produc-
tion was measured at 540 nm with a microplate spectrophotometer
(SAFAS). Before the reaction, nitrates are converted to nitrites by ni-
trate reductase. A standard curve, performed with a known amount
of nitrites was used to quantify the concentration of nitrates+
nitrites.2.12. Measurement of reduced glutathione, alanine and L-arginine
Glutathione (GSH), alanine and L-arginine concentrations were
determined by mass spectrometry on whole lysates of SH-SY5Y
cells. Brieﬂy, cells were harvested by trypsinization with cold trypsin
and were resuspended in a cold lysate medium (sucrose 250 mM,
EGTA 0.5 mM, HEPES 10 mM, Triton 10%, antiproteinase 1×). Lysates
were centrifuged (16,000 g, 5 min, 4 °C) and the supernatant was im-
mediately frozen in liquid nitrogen and kept at −80 °C until mea-
surement. Cell lysates were deproteinized and GSH, alanine and
L-arginine concentrations were determined by mass spectrometry
on an API 3000 triple quadripole apparatus (Applied Biosystems)
using standard laboratory procedures.0
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Fig. 1. Cellular metabolism of the m.3243A>G SH-SY5Y cybrid cells. (A) Glucose con-
sumption, pyruvate, lactate and alanine production in controls (open bars), 70% M
cybrids (gray bars) and 100% M cybrids (black bars). (B) Enzymatic activity of lactate
dehydrogenase in controls (open bars), 70% M cybrids (gray bars) and 100% M cybrids
(black bars). The results are expressed as fold changes relative to mean control cell
values. Data are presented as means±sem of 4 independent experiments. Differences
between groups were evaluated by a Mann–Whitney statistical test, the asterisk (*) in-
dicates signiﬁcant differences (pb0.05) compared to controls.3. Results
3.1. The m.3243A>G mutation induces a metabolic switch in SH-SY5Y
cybrid cells
The m.3243A>G mtDNA mutation is often associated with the
MELAS syndrome, which is characterized by severe mitochondrial
dysfunction associated with lactic acidosis and stroke-like episodes.
The entire mtDNA sequencing of the SH-SY5Y cybrid cells (see sup-
plemental Table 1) showed no other pathogenic mutations or vari-
ants that could modify mitochondrial expression, such as the
12300G>A, predicted to act as a mutant suppressor [27]. The se-
quence was deposited in the GenBank database under GenBank num-
ber JN989561. The quantiﬁcation of mtDNA mutation load was
carried out by ﬂuorescent RFLP (restriction fragment length polymor-
phism) and monitored on a regular basis during the experiments as
shown before [25].
To validate the cybrid cells as a MELAS model, and to determine
whether the introduction of the m.3243A>G mutation in SH-SY5Y
cells induces metabolic modiﬁcations; several metabolites including
glucose, pyruvate and lactate were assayed in controls, heteroplasmic
cybrids (70% M) and apparently homoplasmic cybrids (100% M). The
glycolytic metabolism increased signiﬁcantly in mutant cells (Fig. 1).
After 3 days of culture, the glucose consumption was signiﬁcantly0.0
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Fig. 2. Oxygen consumption assays on cybrid cells. (A) Mitochondrial oxygen con-
sumption measured on digitonin-permeabilized controls (open bars), 70% M cybrids
(gray bars) and 100% M cybrids (black bars). The results show complex I, complex II
and complex IV-dependent respiratory rates. (B) Total ATP content of controls (open
bars), 70% M cybrids (gray bars) and 100% M cybrids (black bars). The results are
expressed as fold changes relative to mean control cell values. The data are presented
as means±sem of 4 independent experiments. Differences between groups were eval-
uated by a Mann–Whitney statistical test, the asterisk (*) indicates signiﬁcant differ-
ences (pb0.05) compared to controls.
Fig. 3. The m.3243A>G mutation affects the structure of the mitochondrial network. Control SH-SY5Y, 70% M cybrids and 100% M cybrids were cultured on chamber-slides (Lab-Tek). Mitochondria were labeled with MitoTracker® Green
100 nM, 15 min in DMEM-High Glucose, 10% FBS. Representative images are shown here. A color code indicates the different types of mitochondria. Connected mitochondrial networks are shown in purple/blue whereas isolated and spher-
ical mitochondria are shown in yellow/red. The histogram shows the percentage of connected or unconnected mitochondria per cell line. The results are the means of two independent experiments.
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1024 V. Desquiret-Dumas et al. / Biochimica et Biophysica Acta 1822 (2012) 1019–1029higher in mutant cells relative to controls: 3.5 fold for 70% M cybrids,
and nearly 6.5 fold for 100% M cybrids (Fig. 1A). Pyruvate production
was not modiﬁed in 70%M cybrids but was slightly decreased in 100%
M cybrids. Alanine concentration was signiﬁcantly higher in 100% M
cybrids. These ﬁndings underscore the major metabolic adaptation
of mutant cells towards glycolysis, with a derivation of pyruvate
from the Krebs cycle to the production of lactate and alanine, as com-
monly seen in MELAS patients. Lactate dehydrogenase (LDH) activity
increased signiﬁcantly in 70% M as well as 100% M cybrids, emphasiz-
ing the increase in the glycolytic metabolism (Fig. 1B).
3.2. Mitochondrial impact of the m.3243A>G mutation on SH-SY5Y cells
depends on the mutant load
To investigate the metabolic switch towards glycolysis induced by
the introduction of the m.3243A>GmtDNAmutation in SH-SY5Ymu-
tant cells, we studied the mitochondrial oxidative metabolism of the
cybrids. In 100% M cybrids, respiratory rates supported by complexes
I and II were 50% lower compared to control cells, whereas respiration
with complex IV substrates (ascorbate+TMPD) was unaffected.
However, in 70% M cybrids, respiratory rates driven by complexes I
and IV increased signiﬁcantly with the malate and pyruvate respira-
tion being 2.5 times greater than in control cells (Fig. 2A). These re-
sults demonstrate that, in 100% M cybrids, the metabolism relies mainly
on glycolysis because of mitochondrial respiratory chain dysfunction.
The increased glycolytic metabolism in 70% M cybrids is correlated with
an increase of respiratory chain activity. We hypothesize that in these
cells, the oxidative phosphorylation of the remaining 30%wild typemito-
chondria compensates the energetic defect due to the mutant load. To0
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Fig. 4. Respiratory chain complex activities and assembly of the cybrid cells. (A) Maximal a
100% M cybrids (black bars). (B) Representative western blot analysis of subunits of comp
DNA-encoded) and V (F1α) and of a reference loading protein (α-tubulin). (C) Blue-Native
complexes and sub-complexes were visualized by enhanced chemiluminescence after prim
complex II used as loading reference).investigate the consequences of themitochondrial dysfunction on energy
production, we measured the total ATP content of mutant cybrids and
controls (Fig. 2B). ATP levels were not lower in the mutant cybrids com-
pared to controls, underlining the crucial compensatory role of glycolysis
in the energetic metabolism of mutant cells.
In addition, the analysis of the mitochondrial network showed
that in 70% M and 100% M cybrids, the number of unconnected and
fragmented mitochondria was 48% and 26% greater, respectively,
than in controls (Fig. 3). This indicates that the mutation alters mito-
chondrial dynamics and fragmented mitochondria were much higher
in 70% M compared to 100% M.
The maximal enzymatic activities of respiratory chain complexes I,
II and IV were signiﬁcantly higher in 70% M cybrids than in controls
(Fig. 4A). In 100% M cybrids, the activities of complexes I and IV
were decreased, complex I being the most affected, with a residual ac-
tivity of 25%. These results correlated with the western blot analysis
of the quantity of respiratory chain complexes (Fig. 4B). Complex IV
(COXII) and complex I (20 kDa) subunits were increased in 70% M
cybrids, but severely reduced in 100% M cybrids compared to con-
trols. It has been suggested that residual COX activity and the pres-
ence of COX-positive ﬁbers in muscle tissue from MELAS patients
may be involved in the pathogenesis of this disorder [8]. To discrimi-
nate between the effects of the mutation on COX activity with respect
to the mtDNA-encoded and the nuclear DNA-encoded subunits, we
quantiﬁed the protein expression of COXII, which is mtDNA-
encoded, and that of COXIV, which is nuclear DNA-encoded. The ex-
pression of the COXII subunit decreased in 100% M cybrids whereas
COXIV appeared to be strongly expressed (Fig. 4B). This highlights
the selective effect of the m.3243A>G mutation on mtDNA-encodedontrol
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Fig. 5. Oxidative stress measurements in cybrid cells. (A) The concentration of nitrates+nitrites concentration in the supernatant of controls (open bars), 70% M cybrids (gray bars)
and 100% M cybrids (black bars). (B) GSH concentration in the supernatant of controls (open bars), 70% M cybrids (gray bars) and 100% M cybrids (black bars). (C) Western Blot
analysis of antioxidant mitochondrial MnSOD. The beta subunit of complex V (Vbeta) was used as loading reference. (D) Ratio of aconitase/citrate synthase activity in controls
(open bars), 70% M cybrids (gray bars) and 100% M cybrids (black bars). The results are expressed as fold changes relative to means of control cell values. The data are presented
as means±sem of 4 independent experiments. Differences between groups were evaluated by a Mann–Whitney statistical test; the asterisk (*) indicates signiﬁcant differences
(pb0.05) compared with controls.
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ulatory mechanism of complex IV that compensates for the mito-
chondrial defect through a differential expression of nuclear DNA-
encoded subunits.
Defects in the mtDNA-encoded subunits of respiratory chain
complexes have been shown to interfere with the assembly of sub-
units of complexes I, IV and V [28]. We studied the assembly of respi-
ratory chain complexes using the Blue-Native PAGE technique on
controls, 70% M and 100% M cybrids. Complex I, the largest compo-
nent of the respiratory chain, encompasses 45 structural subunits as-
sembled in a structure of nearly 1000 kDa [29]. The assembly of
nuclear DNA-encoded subunits requires ﬁne coordination with
mtDNA-encoded subunits in a sequential process involving several
assembly intermediates of various molecular weights. In our study,
complex I assembly was altered in mutant cells with the presence
of low molecular weight assembly intermediates, most abundantly
in 100% M cybrids (Fig. 4C). The Blue-Native PAGE results show
that the respiratory chain complex assembly was severely altered
in the mutant cells.
Modiﬁcations of the assembly and activity of the respiratory chain
complexes may impair the respiratory function and lead to oxidative
stress. We used four techniques to measure oxidative stress in the SH-
SY5Y cybrid cells: the nitrite–nitrate assay, the reduction in GSH pro-
duction, the protein expression of MnSOD, and the aconitase/fumarase
ratio (Fig. 5). The results showed that the m.3243A>Gmutation in SH-
SY5Y cells triggered a signiﬁcant decrease of the nitrite–nitrate concen-
tration as amarker of reduced NO synthase activity (Fig. 5A). Moreover,
GSH production was severely decreased in mutant cells compared to
controls (Fig. 5B). However, the expression of MnSOD (amitochondrial
superoxide detoxifying enzyme) remained unchanged in the mutant
cells (Fig. 5C). The decrease of both the GSH concentration and NO
synthase activity strongly suggested that the mutant cells undergo a
nitrosative stress as evidenced by the reduction of the aconitase/citratesynthase ratio in 70%M aswell in 100%M cybrids (Fig. 5D). Indeed, aco-
nitase, a Krebs cycle enzyme, is commonly used as an oxidative stress
biomarker since it is highly sensitive to the presence of ROS. With
the oxidative/nitrosative stress, aconitase undergoes reversible inactiva-
tion of its iron/sulfur clusters, and under conditions of prolonged oxida-
tive/nitrosative stress, irreversible aconitase inactivationmay occur [30].
Aconitase activity was normalized with respect to citrate synthase activ-
ity, another Krebs cycle enzyme that does not contain an Fe/S center
and is thus insensitive to ROS. The decreased aconitase/citrate synthase
ratio in cybrids compared to controls (Fig. 5D) is strongly indicative of
the oxidative/nitrosative stress in the mutant cells.3.3. L-arginine treatment improves mitochondrial enzyme activity and
increases the formation of supercomplexes
Since NO is a potent regulator of the mitochondrial energetic me-
tabolism, the signiﬁcant decrease of NO synthase activity observed in
the SH-SY5Y cybrids could lead to a respiratory chain defect. To com-
pensate the reduced NO synthesis in the cybrids, the cells were incu-
bated with 1 mM L-arginine (an NO-donor) for 3 days. The L-arginine
levels were higher in treated cybrid cells and controls versus
untreated cells, with an increase of L-arginine concentrations of 70%,
127% and 148% in controls, 70% M and 100% M cybrids, respectively
(data not shown). L-arginine treatment led to a signiﬁcant increase
of complex I activity in controls and 100% M cybrids, with a 2-fold
change in treated versus untreated cells, but did not affect the 70% M
cybrids (Fig. 6A). Complex IV activity was higher in L-arginine-treated
control cells but not in mutant cells (Fig. 6B). L-arginine did not modify
the assembly of complex IV in controls or in cybrids (Fig. 6D). However,
although L-arginine did not increase the activity of the respiratory com-
plexes in 70%M cybrids, it stabilized the formation of supercomplex I:III
(Fig. 6C).
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Fig. 6. Mitochondrial respiratory chain enzyme assays and assembly of the arginine-treated cybrid cells. (A) The ratio of complex I/citrate synthase in controls (open bars), and in
arginine-treated 70% M cybrids (gray bars) and 100% M cybrids (black bars). (B) The ratio of complex IV/citrate synthase in controls (open bars), and in arginine-treated 70% M
cybrids (gray bars) and 100% M cybrids (black bars). The results are expressed as fold changes relative to means of control cell values. The data are presented as means±sem
of 4 independent experiments. Differences between groups were evaluated by a Mann–Whitney statistical test; the asterisk (*) indicates signiﬁcant differences (pb0.05) compared
with controls and the sharp sign (#) indicates signiﬁcant differences between treated and untreated cells (pb0.05). (C) Blue-Native PAGE analysis of complex I assembly in
arginine-treated cybrid cells. The holoenzyme complexes and sub-complexes were visualized by enhanced chemiluminescence after primary antibody incubation (NDUFB6).
(D) Blue-Native PAGE analysis of complex IV assembly of arginine-treated cybrids (COXI antibody).
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dysfunction
For mutant cells carrying the heteroplasmic mtDNA deletion, the
ketogenic medium has been shown to shift the heteroplasmy level to-
wards the wild type suggesting that a ketogenic diet may represent
an interesting therapeutic approach in mtDNA-related diseases [31].
Since the mutant cells rely on glycolysis, we hypothesized that cultur-
ing mutant cells in a low-glucose medium forcing the cells to use ox-
idative phosphorylation would favor wild type cells and thereby
reduce the mutant load. To test this hypothesis, the apparently homo-
plasmic 100% M cybrids were kept in low-glucose medium (0.5 g/l)
for 4 weeks. After a high mortality phase, clones progressively
appeared and ﬁnally recovered the same growth rate as the 70% M
cybrids. The quantiﬁcation of the mutant load revealed that the het-
eroplasmy level shifted to 90% M cybrids in these cells (Fig. 7A). De-
spite a longer four-week period of incubation in a low-glucose
medium, the heteroplasmy level did not fall below 90% M. Table 1
shows that in 90% M cybrids, the enzyme activity of complex I was
improved and complex IV was restored compared with 100% M
cybrids. Moreover, in the 90% M cybrids, we observed an increase in
the holoenzyme forms of complexes I and IV compared with 100%
M cybrids (Fig. 7).
4. Discussion
The consequences of the m.3243A>G mitochondrial mutation
have been extensively studied on skin ﬁbroblasts or osteosarcoma
143TK− derived cybrid cells. The mutation essentially inhibits mito-
chondrial protein synthesis with a deﬁciency of aminoacylation, lead-
ing to complex I deﬁciency [15,16]. However, the consequences of themutation on neuronal cells close to the clinical MELAS phenotype
have not yet received much attention. We have therefore created a
neuronal-like model of the MELAS syndrome, which is known to be
associated with recurrent focal neurological deﬁcits and stroke-like
episodes. The neuronal-like model consists of a series of transmito-
chondrial cybrid cell lines combining the nuclear background of a
neuroblastoma cell line (SH-SY5Y) and enucleated ﬁbroblast mito-
chondria carrying the m.3243A>G mutation at 70% and 100% mutant
loads.
Our study shows as expected that the biochemical consequences
of the m.3243A>G mutation in SH-SY5Y cells depend on the level of
heteroplasmy, and that homoplasmic mutant cells are subject to se-
vere reduction of respiratory chain complex activity, with complexes
I and IV being the most affected. COXIV, a nuclear DNA-encoded com-
plex IV subunit, is differentially expressed compared to COXII, an
mtDNA-encoded subunit. This is in accordance with a previous
study [32], suggesting that the m.3243A>G mutation accelerates
mtDNA-encoded protein degradation and leads to a disequilibrium
between nuclear DNA-encoded and mtDNA-encoded subunits, there-
by impeding respiratory chain function. This hypothesis is reinforced
by our Blue-Native PAGE ﬁndings that show that complex I is misas-
sembled in 100% M cybrids. Surprisingly, complex II driven respira-
tion is decreased by 50% in 100% M cybrids without reduction of
enzymatic maximal activity emphasizing a functional effect on the re-
spiratory chain when the mutation is apparently homoplasmic; a
similar complex II reduction has been reported in a study on brain
capillary endothelial cybrid cells carrying the m.3243A>G mutation
[18].
In our model, the severe mitochondrial respiratory chain defects
provoked by the m.3243A>G mutation were compensated by an in-
crease in the glycolytic metabolism that ensured normal ATP levels
ComplexI 
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Control 70%M 100%M
900 kDa
holoenzyme
400 kDa
intermediate
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(COXI antibody)
90%M
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Fig. 7. Blue-Native PAGE analysis of respiratory chain complex assembly of 90% M
cybrids compared to 70% and 100% M cybrid cells and control cells. All cell lines were
cultured in the same media. Holoenzyme complexes and sub-complexes were visual-
ized by enhanced chemiluminescence after primary antibody incubation (NDUFB6 for
complex I and COXI for complex IV).
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cybrids, by high lactate and alanine concentrations as described in MELAS
patients, in whom chronic lactic acidosis leads to cellular dysfunction [33].
Ketogenic diets reduce the percentage of deleted mtDNA mole-
cules in the presence of large-scale heteroplasmic deletions [31].
Moreover, such diets slow down the progression of myopathy in the
Deletor mouse model, a disease model for progressive, late-onset mi-
tochondrial myopathy [34], and increase mitochondrial glutathione
levels [35]. In our study, the respiratory defect caused by the
m.3243A>G mutation in 100% M cybrids was compensated by in-
creased glycolysis. We therefore hypothesized that metabolic inter-
ventions may effectively restore mitochondrial function in SH-SY5YTable 1
Enzymatic respiratory chain complexes I and IV of the 90% M cybrid cells. Enzymatic
activities of complexes I and IV normalized with citrate synthase activity of controls,
70% M cybrids, 90% M cybrids (in bold) and 100% M cybrids. The results are expressed
as fold changes relative to means of control cell values. The data are presented as
means±sem of 4 independent experiments. Differences between groups were evalu-
ated by a Mann–Whitney statistical test; the asterisk (*) indicates signiﬁcant differ-
ences (pb0.05) of mutant cells compared with control cells; the sharp sign (#)
indicates signiﬁcant differences between 100% M cells cultured in high glucose medi-
um and the 90% M (derived from 100% M cells) cultured in low glucose (pb0.05).
Complex activity i citrate synthase ratio (relative to control cell)
Complex I Complex IV
Control 1.00±0.16 1.00±0.15
70% M 1.67±0.20⁎ 2.53±0.16⁎
100% M 0.19±0.02⁎ 0.52±0.04⁎
90% M 0.53±0.04⁎,# 0.72±0.12#cybrid cells. A small decrease of the mutant load in cells may be
enough to rescue the biochemical phenotype and then has the poten-
tial to modulate the clinical phenotype if you pass under the patho-
genic threshold of the mutation. We ﬁrst tested metabolic switching
by maintaining the apparently homoplasmic mutant cybrids in a
low-glucose medium (0.5 g/l instead of 4.5 g/l). After 4 weeks in
this culture medium, the mutant load shifted from 100% M to 90%
M, accompanied by the increased formation of complex I holoen-
zyme, improving complex I activity. However, keeping the cybrids
for a longer time in the selective medium did not decrease the hetero-
plasmy level below 90% M.
The reason why we were not able to reduce below 90% the mutant
load even a after long term exposure is not well understood. Maybe
more severe metabolic conditions i.e. no glucose or with the use of
galactose should be a better way in reducing the mutant load. Further
experiments are needed to better understand how heteroplasmy
shifting might be useful. Indeed, the concept of reducing the mutant
load and then increasing normal mtDNA as a means of correcting
the biochemical defect has generated a lot of interest [31].
Interestingly, the mitochondrial network was analyzed showing
that in mutant cybrids, the number of fragmented and unconnected
mitochondria was higher compared to control cells, as an indication
of the alteration of mitochondrial dynamics due to the m.3243A>G
mutation.
Moreover, the percentage of fragmented mitochondria was much
higher in the heteroplasmic mutant 70% M than the apparently
homoplasmic 100% M. The aconitase/citrate synthase ratio was used
as an index of ROS generation in cybrid cells. In parallel to the level
of unconnected mitochondria in 70% M, the reduction of the aconi-
tase/citrate synthase ratio was higher in 70% M compared to 100%
M cybrids suggesting a direct link between ROS production and the
modiﬁcations of mitochondrial fusion/ﬁssion machinery. This situa-
tion is similar to a previous observation showing that a heteroplasmic
mutation in ND5 gene carrying about 72% of mutant mtDNA appeared
to be more deleterious producing more ROS and promoting tumori-
genesis than the same mutation in a near homoplasmic state [36].
Increased oxidative stress and lipid peroxidation has been
reported in cybrid cells harboring 90% of mutated mtDNA copies
[37]. Moreover, oxidative damages were signiﬁcantly increased
around stroke like brain lesions in MELAS patients [38]. In our
model of neuronal-derived mutated cybrids, the mitochondrial respi-
ratory chain impairment led to oxidative/nitrosative stress as shown
by the reduction in the GSH level, in NOS activity and in the aconi-
tase/citrate synthase activity ratio.
It has been hypothesized that oxidative stress may aggravate mi-
tochondrial bioenergetic defects and inhibit the ubiquitin–protea-
some pathway and protease activity in human cells harboring
mutant mtDNA, thereby leading to the accumulation of misfolded
proteins, a condition that could trigger mitochondrial apoptosis
[39]. Nitrosative stress may also be deleterious since S-nitrosylation
has been shown to compromise the dynamics of the mitochondrial
ﬁssion–fusion process, altering protein folding and leading to neuro-
toxicity [40]. However, nitric oxide is also an important second mes-
senger especially in endothelial and neuronal cells. Indeed, increase
in NO production through the stimulation of eNOS activity has been
reported to protect against stroke through a wide range of cellular ef-
fects, including vasodilation, antithrombotic, anti-inﬂammatory and
anti-proliferative activities [41]. One of the striking clinical symptoms
in MELAS is the occurrence of stroke-like episodes, which is supposed
to be linked to the NO metabolism [11]. Our study showed that NOS
activity was signiﬁcantly reduced in mutated cybrid cells, resulting
in a decrease in the NO level. We therefore hypothesized that restor-
ing the NO level in mutant cells would reduce mitochondrial dysfunc-
tion, and then as a consequence will be beneﬁcial for ameliorating the
neuronal and endothelial functions in MELAS patients. The action of
L-arginine as an NO donor [11] makes it a good candidate for the
1028 V. Desquiret-Dumas et al. / Biochimica et Biophysica Acta 1822 (2012) 1019–1029treatment of the stroke-like episodes inMELAS patients. Indeed, the efﬁ-
cacy of L-arginine supplementation in MELAS patients, carrying either
the m.13513G>A or the m.3243A>G mutations, has been shown to be
beneﬁcial in both short and long term treatments [11,12,42]. L-arginine
has been proposed as a treatment for MELASm.3243A>G syndrome pa-
tients during the acute stroke phase or long termuse [9,12,22]. L-arginine
is administrated either by intravenous injections (0.5 g/kg/day) or orally
between crises at 0.15–0.3 g/kg/day [22]. Since NO is the vasodilator, loss
of NO would result in chronic vasoconstriction and transient ischemia.
As the substrate of NOS, L-arginine should stimulate NOS, to generate
more NO and alleviate the vasoconstriction. However, the consequences
and biochemical rationale of L-arginine therapy onmitochondrialmetab-
olism has not yet been studied. In our in vitro neuronal-like model,
L-arginine treatment improved complex I enzymatic activity and
stabilized the formation of supercomplexes I+III, which have re-
cently been shown to beneﬁt cell metabolism while reducing the
formation of ROS [43].
5. Conclusions
Our results emphasize the impact of the m.3243A>G mutation on
neuronal mitochondrial metabolism and the usefulness of the MELAS
neuronal-like model for the evaluation of therapeutic strategies
against the disease. We tested two strategies likely to compensate
for the biochemical defects produced by the mitochondrial mutation.
The ﬁrst strategy, involving the use of a low-glucose medium, shifted
the heteroplasmy of the cybrids towards the wild type, signiﬁcantly
improving the mitochondrial function deteriorated by the
m.3243A>Gmutation. The second strategy, based on L-arginine treat-
ment, improved the bioenergetic parameters of the cybrids, in which
the mutation had led to defective NO metabolism, thus conﬁrming
the hypothesis that L-arginine, an NO donor, may constitute an effec-
tive treatment for the stroke-like episodes in the MELAS syndrome.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2012.01.010.
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